One study analysed the adverse event rate following 12 years of Adalimumab (TNF inhibitor) exposure from 71 global clinical trials in 23,458 patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), psoriatic arthritis, psoriasis (Ps) or Crohn’s disease (CD) [96]. This evidence concerns the gene TNF and rheumatoid arthritis.